

specification on page 51, lines 10-24. Applicants submit that this rejection has been obviated by the amendment to the claim and respectively request withdrawal of the rejection.

In the Drawings


The Examiner has maintained her objection to the drawings under 37 C.F.R. § 1:84(U)(1) based on different sections of the same figures that have lower case letters instead of capital letters. Accordingly, Applicants submit herewith a corrected set of drawings.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 02-2327**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

If the Examiner believes that a telephone conference would expedite the prosecution of this application, please call the undersigned at (617)-679-2079.

Respectfully submitted,

Date: 11/20/03



Niki D. Cox, Esq.
Reg. No. 42, 446
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-2079 (Direct)
(617) 679-2838 (Facsimile)

Version Showing Marked Up Changes

25. (Amended) A pharmaceutical composition which comprises an effective amount of a gamma common chain blocking agent wherein the agent is a monoclonal antibody selected from the group consisting of:

- (a) a monoclonal antibody that cross competes with monoclonal antibody CP.B8 produced by hybridoma cell line ATCC No. HB-12107 for binding to gc chain, and also cross competes with Fab, F(ab')₂, and Fv fragments and conjugates of said CP.B8;
- (b) a monoclonal antibody that cross competes with monoclonal antibody CQ.C11 produced by hybridoma cell line ATCC No. HB-12105 for binding to gc chain, and also cross competes with Fab, F(ab')₂, and Fv fragments and conjugates of said CQ.C11;
- (c) a monoclonal antibody that cross competes with monoclonal antibody AF.F4 produced by hybridoma cell line ATCC No. HB-12104 for binding to gc chain, and cross competes Fab, F(ab')₂, and Fv fragments and conjugates of said AF.F4; and
- (d) a monoclonal antibody that cross competes with the monoclonal antibody AE.C9 produced by hybridoma cell line ATCC No. HB-12106 for binding to gc chain, and cross competes with Fab, F(ab')₂, and Fv fragments and conjugates of said AE.C9.